110 related articles for article (PubMed ID: 9168882)
1. Amplification of recombinant adenoviral transgene products occurs by inhibition of histone deacetylase.
Dion LD; Goldsmith KT; Tang DC; Engler JA; Yoshida M; Garver RI
Virology; 1997 May; 231(2):201-9. PubMed ID: 9168882
[TBL] [Abstract][Full Text] [Related]
2. The histone deacetylase inhibitor sodium butyrate inhibits baculovirus-mediated transgene expression in Sf9 cells.
Peng Y; Song J; Lu J; Chen X
J Biotechnol; 2007 Aug; 131(2):180-7. PubMed ID: 17655959
[TBL] [Abstract][Full Text] [Related]
3. The effects of trichostatin A on the oncolytic ability of herpes simplex virus for oral squamous cell carcinoma cells.
Katsura T; Iwai S; Ota Y; Shimizu H; Ikuta K; Yura Y
Cancer Gene Ther; 2009 Mar; 16(3):237-45. PubMed ID: 18949013
[TBL] [Abstract][Full Text] [Related]
4. Possible mechanism of action of the histone deacetylase inhibitors for the induction of differentiation of HL-60 clone 15 cells into eosinophils.
Ishihara K; Hong J; Zee O; Ohuchi K
Br J Pharmacol; 2004 Jul; 142(6):1020-30. PubMed ID: 15210580
[TBL] [Abstract][Full Text] [Related]
5. Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate.
Sekhavat A; Sun JM; Davie JR
Biochem Cell Biol; 2007 Dec; 85(6):751-8. PubMed ID: 18059533
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of histone deacetylation by butyrate induces morphological changes in Y79 retinoblastoma cells.
Karasawa Y; Okisaka S
Jpn J Ophthalmol; 2004; 48(6):542-51. PubMed ID: 15592778
[TBL] [Abstract][Full Text] [Related]
7. Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy.
Höti N; Chowdhury W; Hsieh JT; Sachs MD; Lupold SE; Rodriguez R
Mol Ther; 2006 Dec; 14(6):768-78. PubMed ID: 16990052
[TBL] [Abstract][Full Text] [Related]
8. The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model.
El-Khoury V; Breuzard G; Fourré N; Dufer J
Br J Cancer; 2007 Aug; 97(4):562-73. PubMed ID: 17667922
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of histone deacetylase inhibitors on phorbol ester- and TGF-beta1 induced murine tissue inhibitor of metalloproteinases-1 gene expression.
Young DA; Billingham O; Sampieri CL; Edwards DR; Clark IM
FEBS J; 2005 Apr; 272(8):1912-26. PubMed ID: 15819885
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors as potential anti-skin cancer agents.
Saunders N; Dicker A; Popa C; Jones S; Dahler A
Cancer Res; 1999 Jan; 59(2):399-404. PubMed ID: 9927053
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors preferentially augment transient transgene expression in human dermal fibroblasts.
Yasukawa K; Sawamura D; Goto M; Nakamura H; Shimizu H
Br J Dermatol; 2007 Oct; 157(4):662-9. PubMed ID: 17711521
[TBL] [Abstract][Full Text] [Related]
12. Effects of histone deacetylase inhibitors on estradiol-induced proliferation and hyperplasia formation in the mouse uterus.
Gunin AG; Kapitova IN; Suslonova NV
J Endocrinol; 2005 Jun; 185(3):539-49. PubMed ID: 15930180
[TBL] [Abstract][Full Text] [Related]
13. A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture.
Niki T; Rombouts K; De Bleser P; De Smet K; Rogiers V; Schuppan D; Yoshida M; Gabbiani G; Geerts A
Hepatology; 1999 Mar; 29(3):858-67. PubMed ID: 10051490
[TBL] [Abstract][Full Text] [Related]
14. Radiation-induced upregulation of gene expression from adenoviral vectors mediated by DNA damage repair and regulation.
Nokisalmi P; Rajecki M; Pesonen S; Escutenaire S; Soliymani R; Tenhunen M; Ahtiainen L; Hemminki A
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):376-84. PubMed ID: 22019240
[TBL] [Abstract][Full Text] [Related]
15. Quantitative and in vivo activity of adenoviral-producing cells made by cotransduction of a replication-defective adenovirus and a replication-enabling plasmid.
Dion LD; Goldsmith KT; Garver RI
Cancer Gene Ther; 1996; 3(4):230-7. PubMed ID: 8853547
[TBL] [Abstract][Full Text] [Related]
16. Trichostatin A and structurally related histone deacetylase inhibitors induce 5-lipoxygenase promoter activity.
Klan N; Seuter S; Schnur N; Jung M; Steinhilber D
Biol Chem; 2003 May; 384(5):777-85. PubMed ID: 12817474
[TBL] [Abstract][Full Text] [Related]
17. Cell cycle arrest and lytic induction of EBV-transformed B lymphoblastoid cells by a histone deacetylase inhibitor, Trichostatin A.
Seo JS; Cho NY; Kim HR; Tsurumi T; Jang YS; Lee WK; Lee SK
Oncol Rep; 2008 Jan; 19(1):93-8. PubMed ID: 18097580
[TBL] [Abstract][Full Text] [Related]
18. Early region 4 modulates adenovirus DNA replication by two genetically separable mechanisms.
Medghalchi S; Padmanabhan R; Ketner G
Virology; 1997 Sep; 236(1):8-17. PubMed ID: 9299612
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells.
Frønsdal K; Saatcioglu F
Prostate; 2005 Feb; 62(3):299-306. PubMed ID: 15389787
[TBL] [Abstract][Full Text] [Related]
20. Enhanced transgene expression in urothelial cancer gene therapy with histone deacetylase inhibitor.
Okegawa T; Nutahara K; Pong RC; Higashihara E; Hsieh JT
J Urol; 2005 Aug; 174(2):747-52. PubMed ID: 16006969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
